Galectin Therapeutics (NASDAQ:GALT) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Galectin Therapeutics (NASDAQ:GALT) posted its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02, MarketWatch Earnings reports.

GALT traded up $0.03 on Thursday, hitting $2.20. 2,443 shares of the stock were exchanged, compared to its average volume of 305,824. Galectin Therapeutics has a 12 month low of $1.65 and a 12 month high of $3.85. The business has a 50-day moving average of $2.29 and a two-hundred day moving average of $2.48. The firm has a market capitalization of $125.57 million, a price-to-earnings ratio of -5.69 and a beta of 2.04.

In other Galectin Therapeutics news, Director Gilbert F. Amelio sold 60,000 shares of the business’s stock in a transaction dated Monday, January 11th. The stock was sold at an average price of $2.17, for a total transaction of $130,200.00. Following the completion of the transaction, the director now owns 60,614 shares of the company’s stock, valued at $131,532.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 40.70% of the stock is currently owned by insiders.

About Galectin Therapeutics

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate is GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

See Also: Special Purpose Acquisition Company (SPAC) – What You Need to Know

Earnings History for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with's FREE daily email newsletter.